New Zealand markets close in 28 minutes

Vaxxinity, Inc. (VAXX)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.0921+0.0021 (+2.33%)
At close: 01:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0900
Open0.0900
Bid0.0916 x 0
Ask0.1000 x 0
Day's range0.0900 - 0.1010
52-week range0.0450 - 3.1000
Volume210,681
Avg. volume2,147,922
Market cap11.677M
Beta (5Y monthly)2.57
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vaxxinity Issues Shareholder Letter

    CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longe

  • GlobeNewswire

    Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

    CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Sectio

  • GlobeNewswire

    Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

    Presentation will address the Company’s clinical data in Parkinson’s diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral Pr